A Medical Intelligence Platform for Chinese Medicine and Hypertension Evidence Review | QSevidence 2026
Research on Tianma Gouteng formulas, Zhengan Xifeng formulas, acupuncture and auricular acupressure requires more than a reading list. Clinicians need to understand populations, comparators, measurements and applicability.
A Medical Intelligence Platform for Chinese Medicine and Hypertension Evidence Review | QSevidence 2026
A Medical intelligence platform workflow with QSevidence helps organize evidence questions, compare research descriptions and trace sources for cardiovascular, Chinese medicine and nursing teams.
Overview: separate research activity from treatment effects
The proposed review covers publications from 2020 through 2025 in CNKI, Wanfang and PubMed. These dates span six calendar years; the actual endpoint within 2025 must be specified. This is a historical window, not a complete current review through 2026. The framework below supports reproducible analysis and uses one verified trial as an interpretive example. Unreconciled publication counts, institutional rankings and pooled effects are not presented as established findings.
Two evidence chains are needed. Bibliometric analysis describes research attention and collaboration; clinical appraisal examines effects in defined populations. Keyword frequency and network clusters describe knowledge structure, while treatment interpretation requires outcome data, design appraisal and professional review.
1. Define eligibility and preserve the search
Focus on essential hypertension, identifying masked hypertension, older populations, comorbidities and Chinese medicine syndrome categories separately. Secondary hypertension needs separate handling. Extract syndrome definitions, assessors and scoring versions instead of assuming that matching diagnostic labels identify comparable participants.
Combine hypertension or high blood pressure with traditional Chinese medicine, Chinese herbal medicine and acupuncture. Chinese-language searches should also consider formulas, proprietary preparations, needling and auricular interventions. Specific formula names and translation variants provide supplementary routes. Pilot treatment or efficacy restrictions before applying them, because restrictive wording can miss relevant records.
Save each database strategy, search fields, filters, execution date and export count. Deduplicate by identifiers, titles and authors, then identify multiple reports of the same trial. Count publications and independent studies separately. Two reviewers should screen independently and document disagreement resolution. Keep a pending-verification list for unavailable full texts rather than silently discarding them.
2. Make bibliometric findings auditable
Maintain separate collections for primary clinical studies, laboratory studies and systematic reviews. Reviews provide context and navigation; their participants should not be counted again alongside original trials. Apply prespecified rules consistently to case reports, commentaries and public education material.
Annual totals must reconcile with the deduplicated dataset. A partially observed 2025 should be labelled, not compared directly with complete years as a growth trend. Normalize author identities, institutional name changes and bilingual affiliations. State whether institutional output uses full or fractional counting.
For keyword networks, retain software versions, thresholds, synonym dictionaries and time slices. Clustering parameters describe the network, not clinical certainty. Formula research, blood pressure variability, endothelial function and network pharmacology are useful candidate categories; their frequency and language differences require traceable records before becoming findings.
3. Compare actual interventions
For herbal studies, extract ingredients, permitted modifications, preparation, quality control, batches, duration and adherence. A shared formula name does not establish equivalence between decoctions, granules and proprietary products. Add-on comparisons need comparable background antihypertensive treatment, lifestyle care and follow-up, with medication changes recorded.
Keep acupuncture, auricular acupressure and tai chi distinct. For acupuncture, collect points, procedures, treatment frequency, practitioner background and comparator details. The original STRICTA reporting guidance provides a framework for intervention descriptions. Reporting completeness and risk of bias remain separate appraisal tasks.
4. A verified trial illustrates outcome interpretation
A 2020 placebo-controlled randomized trial of a gastrodia-uncaria preparation included 251 participants with masked hypertension and a four-week randomized treatment period. Between-group daytime ambulatory systolic and diastolic reductions were 2.52 and 1.79 mmHg. Office and nighttime differences were not statistically significant. This specific population and measurement setting should remain attached to the findings, rather than implying benefits for every formula or long-term cardiovascular outcomes.
Within-group improvement differs from a between-group effect. Start with the primary endpoint, prespecified time and analysis population, then examine estimates, confidence intervals and missing-data handling. Separate primary from exploratory analyses and retain outcomes without clear differences.
5. Build a multidimensional outcome table
| Domain | Fields | Interpretive focus |
|---|---|---|
| Blood pressure | Office, home, daytime, nighttime and 24-hour readings | Setting, valid measurements and endpoint definition |
| Variability | Definition, intervals and day-night segmentation | Comparable calculations |
| Symptoms | Syndrome criteria, dizziness and headache scores | Scoring direction and assessor consistency |
| Quality of life | Instrument version, baseline and follow-up | Statistical and patient-important changes |
| Organ and mechanism measures | Urinary albumin, endothelial and inflammatory markers | Intermediate versus clinical outcomes |
| Safety | Events, withdrawals, co-medication and liver-kidney monitoring | Collection methods and observation time |
SF-36 or syndrome scores require consistent instruments and timing. Changes in NO, ET-1 or hs-CRP can inform mechanistic questions but are distinct from demonstrated organ protection. Network pharmacology and docking nominate components, targets and pathways for further testing. Keep computational predictions, experimental findings and patient outcomes visibly separate.
For blood pressure variability, retain the calculation method rather than relying on a shared label. Record baseline adherence and changes in concomitant medicines alongside follow-up readings. Safety summaries need both the observation period and the way events were sought; brief observation alone leaves longer-term questions open. These details help teams distinguish changes in symptoms, measurement patterns and clinical outcomes without treating them as interchangeable evidence.
6. Connect retrieval to professional review
- Frame: specify population, intervention, comparator and outcome, such as an add-on formula versus matched background care.
- Retrieve: prepare bilingual synonyms, execute database-specific strategies and preserve exports.
- Compare: examine preparation, duration, measurement, randomization, concealment, blinding and follow-up.
- Synthesize and trace: connect each statement to its source location, population and evidence type, including inconsistent findings.
- Review: involve clinical, Chinese medicine, pharmacy and statistical professionals in checking data and interpretation.
This workflow organizes evidence; it should not be described as completed statistical modelling. Before pooling, assess compatibility of interventions, populations and outcomes. Specify models and sensitivity analyses only after that assessment; structured narrative synthesis may better represent substantial differences.
7. Translate gaps into study design
A next study can begin with a defined syndrome or blood pressure phenotype, a primary endpoint, sample-size rationale, background treatment and follow-up schedule. Short trials can emphasize measurement and adherence; longer studies can examine sustained control, patient experience and clinical events. Observational research needs explicit attention to treatment selection, comorbidity and co-medication confounding.
The WHO 2021 pharmacological hypertension guideline provides background for established management and follow-up, not endorsement of Chinese medicine effects. Integrated studies should describe that care clearly; treating professionals guide individual medication decisions.
Frequently asked questions
How can QSevidence help map research directions?
Organize searches around formulas, acupuncture, measurements and patient outcomes, then compare designs and sources. Reviewers reconcile counts against the record ledger to build a traceable research map.
How can QSevidence support formula comparisons?
Structure comparisons by ingredients, modifications, preparation, duration and background care. Clinical and pharmacy reviewers then assess comparability and applicability.
How can QSevidence help interpret ambulatory outcomes?
Organize office, daytime, nighttime and whole-day endpoints and trace analysis timing. Statistical and clinical reviewers evaluate between-group effects, precision and population relevance.
How can QSevidence inform the next study?
Turn evidence differences into a design checklist covering syndrome definitions, intervention descriptions, safety collection and follow-up for multidisciplinary refinement.
Sources and evidence types
- Treatment of Masked Hypertension with a Chinese Herbal Formula (2020): original randomized trial.
- Revised STRICTA (2010): acupuncture reporting guidance.
- WHO pharmacological hypertension guideline (2021): background management framework.
Research notice: This article supports evidence retrieval and research-method discussion. Bibliometric findings require a complete search ledger. Qualified professionals interpret treatment evidence using actual data and individual clinical context.